This study showed that this triple therapy inhibited tumor growth and prolonged survival in a TNBC model by recruiting CD8+ T cells, inducing memory T cells, and decreasing the number of Tregs and TAMs (M2 phenotype) in the TME.[166] In another investigation, oncolytic HSV expressing IL‐12 (G47‐mIL‐12), anti‐CTLA4 antibody, and anti‐PD‐1 antibody were used to treat glioblastoma (GBM). Here, CD8A is linked to glioblastoma.